Cerulean Appoints Susan L. Kelley, M.D., to Its Board of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cerulean Appoints Susan L. Kelley, M.D., to Its Board of Directors

CAMBRIDGE, Mass., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq: CERU ), a leader in Dynamic Tumor Targeting™, today announced the addition of Susan L. Kelley, M.D., to the company's board of directors.

"Susan is a successful oncology drug developer, and she brings a rare breadth and depth of drug development experience to Cerulean's expanding clinical development programs in oncology," said Oliver Fetzer, Ph.D., President and Chief Executive Officer of Cerulean. "With CRLX101 in clinical trials in three lead indications, including the recently launched randomized Phase 2 trial in 3 rd /4 th line renal cell carcinoma, and CRLX301 expected to enter the clinic before year-end, we have many opportunities to benefit from Susan's wisdom."

Dr. Kelley has been developing drugs in oncology and immunology for over 25 years. From 2008 to 2011, she was Chief Medical Officer of the Multiple Myeloma Research Consortium and its sister organization, the Multiple Myeloma Research Foundation. From 2001 to 2008, she held positions of increasing responsibility at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma, including Vice President, Global Clinical Development and Therapeutic Area Head – Oncology, where she led the Bayer team responsible for the development and worldwide regulatory approval of Nexavar® (sorafenib), including a renal cell carcinoma indication. She also held positions of increasing responsibility at Bristol-Myers Squibb in Oncology and Immunology drug development from 1987 to 2001.

Dr. Kelley currently serves as a member of the Board of Directors of ArQule and Alchemia, oncology-focused biotechnology companies.

Dr. Kelley received her M.D. from Duke University School of Medicine. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine.

"The unique Cerulean technology platform has generated a pipeline of nanoparticle-drug conjugates, or NDCs, with the potential to make a substantial difference for people living with cancer," said Dr. Kelley. "I look forward to working together with the rest of the Directors and the Management Team to advance CRLX101, CRLX301 and subsequent NDCs through clinical development towards regulatory approval."

"Dr. Kelley is the fourth independent director to join Cerulean's Board in 2014," said Alan Crane, Chairman of Cerulean's Board of Directors. "As part of becoming a public company, we appointed three experienced public company directors with extensive industry and company building experience: Paul Friedman, former CEO of Incyte, Bill McKee, former CFO of Barr, and Bill Rastetter, former CEO of Idec. They already have contributed greatly, and we look forward to Susan's contributions."

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of which aim to unlock the power of combination therapy. For more information, please visit www.ceruleanrx.com .

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2014 and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Aurora Krause Cerulean Pharma Inc. Corporate Communications 617-551-9627

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 16

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 150

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 132

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 127

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 91

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 28

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 213

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 144

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading

Top 5 Most Recently Viewed Articles

PHX Minerals Set to Release Full-Year 2024 Financial Results

Updated Category News Views 176

PHX Minerals Reveals Upcoming Financial Results Announcement PHX MINERALS INC., commonly known as PHX, is preparing to share its financial results for the year that concluded on December 31, 2024. This announcement is eagerly awaited by investors and stakeholders, marking a significant moment in understanding the company’s financial health and future outlook. Details of...

Continue Reading
Baird Optimistic on First Industrial Realty Trust Growth Ahead

Updated Category News Views 183

Baird's Positive Outlook for First Industrial Realty Trust Baird has reaffirmed its positive stance on First Industrial Realty Trust (NYSE: FR), maintaining an Outperform rating alongside a $61.00 price target. The firm's analysis indicates that the company's core portfolio is projected to deliver a stable 6% annual growth, signaling strong performance prospects for...

Continue Reading
Aprea Therapeutics Secures $3.1 Million Investment for Growth

Updated Category News Views 151

Aprea Therapeutics Secures $3.1 Million Investment Aprea Therapeutics, Inc. (Nasdaq: APRE), a forward-thinking clinical-stage biopharmaceutical company, has announced a notable private placement aimed at enhancing its development of innovative cancer treatments. This financing comes from a blend of new and existing investors, reflecting confidence in the company’s...

Continue Reading
Silal and SVG Forge New Paths in Sustainable Agriculture

Updated Category News Views 174

Silal and SVG Forge New Paths in Sustainable Agriculture In a significant development for the agricultural sector, Silal, a leading agri-food and technology company, and Shouguang Colorful Manor Modern Agriculture Co., Ltd (SVG) have entered a joint venture that stands to revolutionize sustainable agriculture practices. This landmark agreement was witnessed by eminent...

Continue Reading